Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658874 | 1.00 | MAPT (0.54) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL30658857 | 0.80 | MAPT (0.47) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL15621159 | 0.80 | MAPT (0.47) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL30658872 | 0.77 | KDM4E (0.58) | MAPTKDM4EPOLBCYP1A2CYP3A4 | |
| SCHEMBL19610809 | 0.77 | KDM4E (0.58) | MAPTKDM4EPOLBCYP1A2CYP3A4 | |
| SCHEMBL30658791 | 0.76 | MAPT (0.45) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL15619940 | 0.76 | MAPT (0.45) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL19620504 | 0.74 | TP53 (0.43) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL19620635 | 0.74 | TP53 (0.43) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL29852012 | 0.74 | MAPT (0.43) | MAPTSMN1; SMN2TP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345596-B1 | INHIBITORS OF BETA-HYDROLASE FOR TREATMENT OF CANCER | RHODE ISLAND HOSPITAL (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10106532-B2 | Inhibitors of beta-hydroxylase for treatment of cancer | MIDWESTERN UNIVERSITY (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3345596-A2 | INHIBITORS OF BETA-HYDROLASE FOR TREATMENT OF CANCER | RHODE ISLAND HOSPITAL (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20180009798-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | MIDWESTERN UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| EP-2897607-B1 | INHIBITORS OF BETA-HYDROLASE FOR TREATMENT OF CANCER | RHODE ISLAND HOSPITAL (US) | 2017-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106532-B2 | Inhibitors of beta-hydroxylase for treatment of cancer | ASPH, CYP46A1, ALDH7A1 | MAPT 3252/4885SMN1; SMN2 3703/4885TP53 873/4885 |
| US-20180009798-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | ASPH, CYP46A1, ALDH7A1 | MAPT 3252/4885SMN1; SMN2 3703/4885TP53 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.